Hera, recently raised $2 million in seed funding, which is currently being utilized to complete the company's second clinical trial in patients. Hera is currently raising a Series-A round to expand the clinical trials and commercialize the test. The company has recently formed a scientific advisory board, composed of top researchers and practitioners in the field, which will provide Hera with additional expertise and outside perspective, as they move forward with their development.